This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MICHAEL E. OSBAND, MD
Division of Pediatric Hematology/Oncology Boston University School of Medicine Boston City Hospital 80 E Concord St Boston, MA 02118

Am J Dis Child. 1986;140(3):191.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Sir.—The optimal treatment of patients with histiocytosis X remains uncertain. Preliminary clinical studies^1-6 have demonstrated that a thymic hormone preparation may be a useful therapy for this disease. The Food and Drug Administration is sponsoring a clinical trial of Suppressin A, one such thymic hormone drug. The purpose of this prospective, randomized, double-blind, placebo-controlled study is to determine if Suppressin A is biologically active in histiocytosis X. I am the principal investigator of this study and am writing to you at this time to solicit patient referrals. The study includes both children and adults with histiocytosis X and patients can be either newly diagnosed or recently relapsed. Please write or call me collect ([617] 638-4182) for further information. Thank you very much for your cooperation in this regard. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?